Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

Medicaid plans often put up barriers around newer classes of diabetes medications that offer cardioprotection, according to a ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.